

Prior notification of a concentration
(Case COMP/M.6293 — Thermo Fisher/Phadia)
(Text with EEA relevance)
(2011/C 213/11)

1. On 12 July 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ⁽¹⁾ by which the undertaking Thermo Fisher Scientific, Inc. ('Thermo Fisher', USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of CB Diagnostics Holding AB, the holding company and sole owner of Phadia Holding AB ('Phadia', Sweden) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

- Thermo Fisher: laboratory and life science instruments and related products, including in vitro diagnostics systems,
- Phadia: immunodiagnostic blood test systems to support the clinical (in vitro) diagnosis and monitoring of allergy and autoimmune diseases.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6293 — Thermo Fisher/Phadia, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

⁽¹⁾ OJ L 24, 29.1.2004, p. 1 (the 'EC Merger Regulation').